The Effect of Yohimbine on Cocaine Cue Reactivity
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Stress and cues reminiscent of cocaine use promote craving and relapse in cocaine dependent individuals. In addition, there appears to be gender differences in determinants of relapse to drug use following abstinence in cocaine-dependent individuals. Therefore the purpose of the present study is to study the role of hormonal status on the response to cocaine-related cues with or without stress in cocaine-dependent women and men.
| Condition | Intervention |
|---|---|
|
Cocaine Related Disorders |
Drug: Yohimbine Drug: Placebo |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | SCOR on Sex and Gender Factors Affecting Women's Health |
- Cocaine craving [ Time Frame: Post cocaine cue exposure ] [ Designated as safety issue: No ]Cocaine-dependent participants were pre-treated with either yohimbine or placebo provided subjective ratings of cocaine craving immediately following cocaine cue exposure.
Biospecimen Retention: Samples With DNA
whole blood saliva
| Enrollment: | 113 |
| Study Start Date: | September 2007 |
| Study Completion Date: | August 2012 |
| Primary Completion Date: | August 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1
non-dependent males
|
Drug: Yohimbine
Participants were pre-treated with either yohimbine or placebo.
Drug: Placebo
|
|
2
non-dependent females
|
Drug: Yohimbine
Participants were pre-treated with either yohimbine or placebo.
Drug: Placebo
|
|
3
cocaine dependent males
|
Drug: Yohimbine
Participants were pre-treated with either yohimbine or placebo.
Drug: Placebo
|
|
4
cocaine dependent females
|
Drug: Yohimbine
Participants were pre-treated with either yohimbine or placebo.
Drug: Placebo
|
Detailed Description:
Cocaine dependence is an insidious disease underscored by a strong propensity to relapse despite knowledge of the repercussions of continued drug-use. Stress and cocaine cues produce craving and ultimately relapse in cocaine dependent individuals. Pre-clinical research has demonstrated sex differences in response to cocaine-conditioned cues and cocaine-primed reinstatement, which correlates well with reduced plasma progesterone levels. Interestingly, this is consistent with a growing body of clinical literature indicating that progesterone may decrease the reinforcing properties of stimulants in women. Gender differences in the response to a social stressor and cocaine cues in cocaine-dependent individuals have been demonstrated in human laboratory studies, however, the interaction of stress and cues and the effect of hormonal status on response have not been explored. This study examines the role of hormonal status on the response to cocaine-related cues with or without a pharmacological stressor (yohimbine) in cocaine-dependent women and men. As a further integration of the research focus this study also explores the relationship between impulsivity and craving.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
The study population will include subjects meeting diagnostic criteria for current cocaine dependence (DSM-IV). Subjects will be recruited through local media advertisements (newspaper, radio, and television), the Institute of Psychiatry Center for Drug and Alcohol Programs, the Charleston Center, the Ralph H. Johnson VA Medical Center, and the Dorchester Alcohol and Drug Commission. Women will be included in the study. In our previous studies, approximately 50% of subjects have been female. African Americans will be recruited into the protocol. Charleston's population is 64% Caucasian, 35% African American and 2% Other. In a previous study, 59% of the subjects were women, 36% were White, 62% African American, and 2% Other, and expect that the racial spectrum will be similar.
Inclusion Criteria:
- Subjects must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.
- Subjects must consent to remain abstinent from all drugs of abuse (except nicotine) for a three-day period immediately prior to the CTRC admission. Nicotine dependence can affect HPA function (Baron et al., 1995) therefore it would be ideal to exclude subjects with nicotine use. Because of the high comorbidity of cocaine and nicotine dependence, this would seriously compromise the feasibility of recruitment. Individuals with alcohol dependence will be excluded. However because of the high comorbidity of alcohol use and cocaine dependence, individuals with alcohol abuse will be included. Also, due to the high comorbidity of cocaine and marijuana dependence, and limited evidence that marijuana use affects HPA function, subjects with marijuana dependence will be included.
- Subjects with ADHD will be included. Because ADHD is commonly characterized by impulsivity, ADHD severity ratings will be determined and controlled for in data analysis.
- Subjects must consent to random assignment.
- Subjects must consent to outpatient admission to the CTRC and two overnight admissions to the Medical University Hospital.
Exclusion Criteria:
- Women who are pregnant, nursing or of childbearing potential and not practicing an effective means of birth control.
- Women with premenstrual dysphoric disorder as this may impact on the response to the stress test procedure (Woods et al., 1994).
- Women receiving depot medroxyprogesterone acetate as a form of birth control.
- Subjects with evidence of or a history of significant hematological, endocrine, cardiovascular, pulmonary, renal, gastrointestinal, or neurological disease including diabetes, as these conditions may affect physiological/subjective responses.
- Subjects with Addison's disease, Cushing's disease or other diseases of the adrenal cortex likely to affect hormonal/neuroendocrine status.
- Subjects with a history of or current psychotic disorder or bipolar affective disorder as these may interfere with subjective measurements.
- Subjects with current major depressive disorder or post-traumatic stress disorder as these disorders are associated with characteristic changes in stress response.
- Subjects with panic disorder, as yohimbine may precipitate panic attacks.
- Subjects receiving synthetic glucocorticoid therapy, any exogenous steroid therapy, or treatment with other agents that interfere with hormonal measurements within one month of test session.
- Subjects taking any psychotropic medications,antidepressants, opiates or opiate antagonists because these may affect test response. Subjects taking SSRI's will be included.
- Subjects with any acute illness or fever. Individuals who otherwise meet study criteria will be rescheduled for evaluation for participation.
- Subjects who are obese (BMI>35) as this may interfere with hormonal status.
- Subjects who are unwilling or unable to maintain abstinence from alcohol and other drugs of abuse (except nicotine) for three days prior to the stress task procedure.
- Subjects meeting DSM-IV criteria for substance dependence (other than nicotine, alcohol, marijuana or cocaine as appropriate) within the past 60 days.
Contacts and Locations| United States, South Carolina | |
| Medical University of South Carolina-GCRC | |
| Charleston, South Carolina, United States, 29425 | |
| Principal Investigator: | Kathleen T Brady, M.D., Ph.D. | Medical University of South Carolina |
More Information
No publications provided
| Responsible Party: | Kathleen Brady MD PhD, Medical University of South Carolina |
| ClinicalTrials.gov Identifier: | NCT00535002 History of Changes |
| Other Study ID Numbers: | P50DA016511-1, P50DA016511 |
| Study First Received: | September 21, 2007 |
| Last Updated: | March 27, 2013 |
| Health Authority: | United States: Food and Drug Administration United States: Federal Government |
Keywords provided by Medical University of South Carolina:
|
Cocaine Addiction Cocaine Dependence |
Additional relevant MeSH terms:
|
Cocaine-Related Disorders Substance-Related Disorders Mental Disorders Cocaine Yohimbine Vasoconstrictor Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Dopamine Uptake Inhibitors Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Neurotransmitter Uptake Inhibitors |
Physiological Effects of Drugs Anesthetics, Local Anesthetics Central Nervous System Depressants Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Adrenergic alpha-2 Receptor Antagonists Adrenergic alpha-Antagonists Adrenergic Antagonists Adrenergic Agents Mydriatics Autonomic Agents |
ClinicalTrials.gov processed this record on May 16, 2013